-
Luye Pharma Group Hands Over Seroquel Distribution Rights to DCH Auriga in Singapore
•
China-based Luye Pharma Group announced that it is handing Singapore distribution and marketing rights to the schizophrenia drug Seroquel (quetiapine fumarate immediate-release tablets) and Seroquel sustained release tablets to DCH Auriga. No financials were disclosed. Acquisition and Licensing HistoryLuye acquired exclusive rights to Seroquel from AstraZeneca via a USD 546…
-
RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers
•
China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained two orphan drug designations (ODD) from the US FDA, for the therapy’s potential use against gastric and pancreatic cancers. RC118: Mechanism and DevelopmentRC118, a novel ADC drug candidate co-developed with contract research organization (CRO) Biocytogen,…
-
Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022
•
China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the 2022 European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO). IBI939 Phase Ib Study ResultsA Phase Ib study to evaluate the safety, tolerability, and efficacy of anti-TIGIT candidate IBI939 in combination with sintilimab in patients with…
-
NMPA Extends Validation Period for COVID-19 Antigen Detection Reagents
•
The National Medical Products Administration released a notification extending the validation period of approvals for COVID-19 antigen detection reagents for another six months. Current Approvals and Future PlansThe NMPA has approved 36 COVID-19 antigen detection reagents for marketing in China, with more to come.-Fineline Info & Tech
-
Science Standard Medical Testing Raises Pre-Series A Funding
•
Science Standard Medical Testing, a professional third-party testing institution based in Changzhou, reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round, a private funding backed by Suzhou Xilu Venture Capital Partnership Limited. Ascendin Fund supported the company’s previous angel financing. Company Background and ServicesFounded in 2015,…
-
Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199
•
Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based biotech BeiGene (HKG: 6160, SHA: 688235, Nasdaq: BGNE) to carry out a Phase I clinical study assessing the safety and efficacy of Phanes’ PT199 combined with BeiGene’s tislelizumab in multiple advanced solid tumors. PT199: Mechanism…
-
XtalPi Partners with CTTQ for AI-Driven Small-Molecule Drug Development
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177). The two will work together on the development of small-molecule drugs in the liver disease field. No financial details were disclosed. AI…
-
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
•
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands, and Suzhou (China), announced the conclusion of a Phase I clinical study for its anti-CTLA-4 antibody HBM4003 combined with Junshi Bio’s programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) in advanced melanoma. The study has shown that…
